This was the stock's second consecutive day of losses.

Quest Diagnostics Inc.’s DGX investments in Advanced ... A strong focus on operational excellence is highly encouraging for the stock. Meanwhile, unfavorable solvency and a fierce competitive ...

In the longer term, DGX stock is up 10.5% on a YTD basis, outpacing SPX’s 2.9% dip. Moreover, shares of Quest Diagnostics have surged 29.3% over the past 52 weeks, compared to the 9.8% return ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

The stock, currently trading near its 52 ... The securities firm's analysis indicates that Quest Diagnostics is expected to continue its positive trajectory, supported by several key factors.

Quest Diagnostics (NYSE:DGX ... Street estimates EPS to be $9.71 per share and revenue to be $10.78B. The stock is down 4% in early trading.

Our technical summary section provides analysis on Quest Diagnostics share price buy/sell indicators using real-time data (or discuss the Quest Diagnostics (DGX) stock price today with other investors ...

leading to the stock’s decline today. While the company’s strategic initiatives and focus on advanced diagnostics may position it for future growth, the immediate market response reflects a more ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

stock has rallied 25.2% compared with the industry’s 2.9% growth and the S&P 500 composite’s 10.6% rise. The renowned provider of diagnostic information services has a market capitalization of $18.38 ...